BioNTech SE is a biotechnology company focused on developing and commercializing immunotherapies and vaccines for cancer and infectious diseases. Its current portfolio spans mRNA-based therapies, targeted cancer treatments, cell therapies, antibodies, and small molecules, supported by proprietary research and development capabilities in immunology, genomics, and computational medicine. The company works across oncology and infectious disease programs, including personalized and next-generation treatment approaches designed to address serious unmet medical needs. BioNTech SE also combines clinical development, in-house manufacturing, and collaboration with pharmaceutical partners to advance its product candidates and marketed therapies. Headquartered in Mainz, Germany, BioNTech SE plays a significant role in the global biotechnology market through its focus on innovative immune-based medicines and vaccine technologies.